TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Reduction in Menopause Rating Scale total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Menopause-Specific Quality of Life Questionnaire total score reduction
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: rescue medication consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: end-of-dose failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HBV-DNA undetectable rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in dGEMRIC index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pulmonary arterial pressures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Myocardial Oxygenation (MO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Subjective image quality (IQ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-Dural Puncture Headache (PDPH) incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Onset time of PDPH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of PDPH (NRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C2.5 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: urinary sodium/creatinine ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: s-PTH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: rate of space closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increase in walking speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: energy saving during ambulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: weight saving
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful BP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: In-hospital costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: 90-day readmission rate
Endpoint domain: Adverse events/effects
Primary endpoint: PROM of hip mobility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: PROM of shoulder flexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Patient comfort level
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Frequency of angina episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in urinary incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of P50 suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tIGF‐I, fIGF‐I and IGFBP‐3 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Sensitivity of HPV DNA testing for high-grade SIL or invasive cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of cytology compared to HPV DNA assays
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Days with diarrhoea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: experimental pain measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pupil size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pulse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction of airway resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: incidence of grade 3 neuropathy
Endpoint domain: Adverse events/effects
Primary endpoint: Aneurysm obliteration rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Angiographic stability rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Rate of cured patients without any neurologic sequelae
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Overall observed rate of death or severe neurologic sequelae
Endpoint domain: Mortality/survival
Primary endpoint: Duration of postoperative catheterization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery of intestinal and bladder function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in tactile sensitivity between teeth and implants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PSQI improvement
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: monthly decline rates of reciprocal serum creatinine (1/Cr)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Rate of disease progression in PSPRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of disease progression in SEADL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TcpO2 improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in ischemic symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Willingness to participate in clinical trials
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Occurrence of seizures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Intravenous PCA morphine 24-hour cumulative dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain on visual analog scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adequate haemofilter life span > 24 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Calorie consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: peak GLP-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: postprandial glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean duration to locate a missing diver
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-assessed confidence in locating a missing diver
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: METS (Metabolic Equivalent of Task)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of IPV victimisation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Psychosocial health
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Fecal SCFA concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Bifidobacterium spp. levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RNFL progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of eyes with UCVA of >20/40
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of treated arrhythmias
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Action Research Arm Test (ARAT) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of mammography for invasive and in situ breast cancers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Screen-detectable mean sojourn time of preclinical cancers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of screen-detected in situ cancers that were non-progressive
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: postload glycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: CISI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PICC-related bloodstream infections
Endpoint domain: Adverse events/effects
Primary endpoint: Return to spontaneous sinus rhythm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Recovery of normal LV function (stroke work index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Creatine phosphate levels in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: patients' global assessment of disease activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain visual analog scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: worsening of preexisting AKI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Accuracy of interspinous level identification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum 25(OH)D level >85 nmol/l
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of T1 enhancing lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: MRI disease activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinically driven target lesion revascularization (TLR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: clinically driven target vessel revascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Postoperative Atrial Fibrillation (POAF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Protein oxidation levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: H-reflex amplitudes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Sensitivity of HASTE MRI in diagnosing acute cholecystitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of HASTE MRI in diagnosing acute cholecystitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall accuracy of HASTE MRI in diagnosing acute cholecystitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Class II correction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maintenance of weight loss and behaviour changes
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Overall patient complications
Endpoint domain: Adverse events/effects
Primary endpoint: Eradication rates of H.pylori infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Symptomatic improvement of bloating, belching, and epigastric pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: significant decrease in all-cause death
Endpoint domain: Mortality/survival
Primary endpoint: Mean elimination half-life (t((1/2)))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of HIV‐1‐specific IFN‐gamma‐producing cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: phagocytosis ability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: intestinal microperfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Plasma total antioxidant capacity (TAC) concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent adequate CCs/epoch
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak work per compression cycle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Enamel damage index grades
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relief of nocturia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: homeostasis model of insulin resistance index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Thromboxane production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Prostacyclin production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: anaerobic threshold oxygen consumption (VO2AT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to passage of stool
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Vasoconstrictive potential
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Topical bioavailability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients free of infection at late follow up
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Relative risk reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IgE specific of ovomucoid titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: ISP survival rates
Endpoint domain: Mortality/survival
Primary endpoint: ceramic fracture
Endpoint domain: Adverse events/effects
Primary endpoint: Hypoglycemic events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Days between hypoglycemic events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life score on hospital discharge
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Resting energy expenditure postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 9-year L-Disease Free Survival (L-DFS) rates
Endpoint domain: Mortality/survival
Primary endpoint: Left ventricular dp/dt
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: android-to-gynoid ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of Erectile Dysfunction (ED)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SBM frequencies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean decrease in Daily Record of Severity of Problems (DRSP) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive response in Clinical Global Impressions-Improvement scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Need for antiemetic therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Breaking point during task performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-reported continuous abstinence from smoking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: shorter onset time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: better efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: higher rate of subparaneural spread
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EAT thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: satisfaction with CDSMP
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: self-care behaviour
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Protein adsorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: degree of vascular remodeling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Diagnostic accuracy of soft-tissue radiography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MADRS score improvement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Agreement (w‐kappa) for WORMS features
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity for WORMS features
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity for WORMS features
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of the scratch collapse test for carpal tunnel syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Sensitivity of the scratch collapse test for cubital tunnel syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Accuracy of the scratch collapse test for carpal tunnel syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Accuracy of the scratch collapse test for cubital tunnel syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Quality of post-contrast images
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: five-year risk for CHD
Endpoint domain: Mortality/survival
Primary endpoint: Geometric mean concentration of LH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Geometric mean concentration of progesterone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: activity-index score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: grade of esophagitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: flare at 52 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fear of childbirth as measured by the WDEQ
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Quality of Life (QOL)
Endpoint domain: Life impact
Endpoint subdomain: General outcomes
Primary endpoint: Patient satisfaction measured using Visual Analogue Scale (VAS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: biaxial flexure strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hospital-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Efficacy in suppressing inducible monomorphic VT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prolongation of QTc interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Serious drug-related adverse reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Perception of course quality
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Association with Persuasion/Decision step
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Time taken for gastric volume to decrease to 50% (t0.5)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Improved social and occupational function
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Clinician-rated PTSD symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-rated PTSD symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning
Primary endpoint: Mean duration of female gametocyte carriage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Female gametocyte prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Male gametocyte prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of preinduction anxiety
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of sedation upon entering the OR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean depression and anxiety scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction with CBT intervention
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: combined maintained response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: loss of HBeAg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: development of adefovir resistance
Endpoint domain: Adverse events/effects
Primary endpoint: Mean levodopa dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disability scores reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal Mortality Ratio (MMR)
Endpoint domain: Mortality/survival
Primary endpoint: median rate of clinical vaso‐occlusive events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: inability to attend school due to illness
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Severe intrapartum acidemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apgar <7 at 5 min
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes